The Economic Times
English EditionEnglish Editionहिन्दीગુજરાતી
| 26 September, 2020, 02:08 AM IST | E-Paper

    Divya Rajagopal

    Assistant Editor, ET

    Divya Rajagopal is an Assistant Editor with The Economic Times newspaper based out of Mumbai, India. She writes on intersection of medical science and business.

    Articles by the author

    Supply delays, rise in Covid-19 cases lead to Remdesivir shortageSupply delays, rise in Covid cases lead to Remdesivir shortageJohnson & Johnson starts phase 3 trial of vaccine; could be available for use by early 2021Covid-19: India sees dip in active cases as 1 lakh people recover in a single day
    To get approval in India, vaccines must work in at least 50% casesSeven months into pandemic, finding a hospital bed is still tough in many placesIndia’s coronavirus vaccine pipeline could be one of the largest in the worldWhere are we with coronavirus vaccines? Here are the promising nine
    T cells may be dealing the killer blow to coronavirus more than antibodies, say researchersIndia to be a big hub for production of Russian vaccines: Kirill Dimitriev, CEO, RDIFTesting may become must for arriving international passengersScaling up: Private labs gear up to conduct more Covid-19 tests as prices drop
    Taking the good with the bad: How potential Covid-19 vaccines offered hope and disappointmentSerum Institute of India officially halts the trial of Astrazeneca-Oxford vaccine in IndiaWill follow DCGI order on Oxford Covid vaccine trial: Serum Institute of IndiaSerum Institute of India to also halt trial of the Oxford-AstraZeneca vaccine candidate
    Covid-19 vaccine for masses in India likely only by 2021 end, say expertsActivated form of vitamin D reduced severity of Covid infection: Study in SpainThis is not a killer virus... but will stay here for a long time: Gagandeep KangMaharashtra may reduce Covid-19 testing rates at private labs by 40 per cent
    Trials and Hopes: Way ahead for Covid-19 treatmentFaster antigen tests may be more useful in Covid-19 fight: Research reportIgnore numbers, focus on death count: ExpertsDivert resources to rural India to tackle the pandemic: George Mathew, Medical expert
    Speed over accuracy as a testing strategy can help in better containment of Covid-19: Milind TambeMaharashtra government to retain price cap on private hospitalsThe infection fatality rate of Covid-19 is inversely proportional to testing: StudyLarge metros contribute 11% to the number of total active cases in India
    Indian researchers start trials on saliva-based Covid-19 testingWHO reviews nine vaccine candidates for Covax allianceScarcity of labs may slow down vaccine trialsPharma euphoria may reverse soon, and how!
    Big boys of India's pharmaceutical industry may reshape Indian e-pharmaIndia’s Covid-19 vaccine plan on track, India has a huge capacity: Panel led by Niti AayogHigh sero prevalence in cities indicate India's IFR might be low, despite doubts about under reporting of deathsSerum Institute looking for a $1 billion shot to fight covid, talks on with Blackstone, KKR and others
    Antibodies can protect from Covid-19 reinfection: StudyCovid-19 has infected a large chunk of Pune’s population: Sero Study'India should nurture domestic medical equipment makers'Indian drug companies seek cure for Donald Trump’s 'Buy-American' plan
    BE ties up with Janssen Pharmaceutica NV for coronavirus vaccine productionPoC Covid-19 tests too fail to deliver fast results as India ramps up testingCovid-19: India’s case fatality rate falls below 2% for the first timeIndian companies ready to export coronavirus test kits, target Latin America, Eastern Europe markets
    Coronavirus is making it tough to breathe, even for Indian pharmaceuticalsAre local lockdowns slowing the spread of coronavirus? Here's what the data saysIndia seems to be getting closer to an antidote, even as the coronavirus situation worsensSerum Institute to price Covid-19 vaccine at $3 per dose for India and lower middle income nations
    ‘Globally, companies can produce 2-4 billion Covid vaccine doses by 2021 end’Domestic vaccine makers wait for procurement commitment from government for Covid-19 vaccinesIndian companies making Covid-19 vaccine upset over lack of norms and infrastructureM&M-Skanray Technologies' indigenously designed ventilator fails to meet govt specs
    WHO concerned about India's rising Covid-19 cases and the younger lot catching virusWockhardt snags Covid-19 vaccine manufacturing deal from the UK govtAfter reaching their peaks, is it time for Delhi and Mumbai to witness the flattening of covid curve?GAVI in talks to make Indian vaccine makers join Covax: CEO Seth Berkley
    Coronavirus vaccine race: Are human challenge trials ethical? Experts are dividedIndia to play crucial part in global manufacturing of Covid-19 vaccinesTocilizumab fails to improve condition of severe Covid-19 patientsIndian API makers benefit as global buyers ditch China
    Mumbai Sero Survey suggest half of those in slums already infected and recoveredCoronavirus Vaccine Race: Most of the Covid-19 vaccines are already reservedAfter four months, Mumbai private hospitals get ready for non-Covid workSerum Institute founder Cyrus Poonawalla to keep some vaccine aside for Parsis
    Indian entrepreneur’s stake in US vaccine company soars to Rs 400 croreMuch headway in quest for vaccine: Drugmakers might be one step away from the Covid remedyIndian drug companies start off a price war on experimental Covid-19 drugHepatitis C drug can help improve condition of coronavirus patients: Study
    India's keen to join WHO-Gavi vaccine alliance in bid to keep supply cost effectiveSerum Institute can supply 400 million doses by December, says CEO Adar PoonawallaHow are new vaccines developed? Here is the complete processNovartis turning to technology to manage business: Bertrand Bodson, Chief Digital Officer
    Virus may be widespread, but not too lethal, indicate antibody tests at private labsSerum Institute of India to apply for local trials on Oxford's vaccine by AugustFighting the Covid battle: India gets sites ready for Phase-3 vaccine trialsHuman clinical trials of Gennova’s mRNA COVID-19 vaccine to start by the end of this year
    Search for vaccines hots up as Covid-19 continues to spread and wreak havoc around the worldBCG vaccine being tried for Covid-19 elderly individuals in hotspots in IndiaActivists urge India to push for fair allocation of Covid-19 vaccine under COVAXAnthony Fauci cautiously optimistic: Countries need to pull back to contain the spread
    Drug firms get DGCI nod for Covid drug favipiravir despite inconclusive studyBiocon to take on Roche Pharma with its psoriasis drug to treat moderate to severe Covid patientsBiocon defends limited trial patients for Itolizumab nod, says followed science of "highest order"Covid-19: The frantic search for a cure continues
    BMC to acquire 20,000 doses of Tocilizumab even as trials yet to determine efficacyImmunologists call for a study on the role of T cells in protecting people against Covid-19Mumbai company working on horse antibodies Covid treatmentNPPA asks Remdisivir drug makers to ensure transparency after complaints about black marketing
    Drug controller asks states to enforce maximum retail price for RemdesivirSanofi halts trials of IL-6 drug for Covid-19, India to continue with trial of another drug of similar classAIIMS, Vizag Hospital yet to approve trials of locally-made Covid vaccineAs demand sputters, ventilator makers want export ban to go
    NIH and DBT to review vaccine candidates for Covid-19 this weekTwo weeks to start the trial, six months at least to finish: ExpertsExperts in two minds over ICMR's August 15 date for Covid-19 vaccine launchDrug makers get nod to raise one-time price increase on heparin injections
    The Economic Times